GB1445283A - Biphenyl derivatives and pharmaceutical compositions thereof - Google Patents

Biphenyl derivatives and pharmaceutical compositions thereof

Info

Publication number
GB1445283A
GB1445283A GB3601374A GB3601374A GB1445283A GB 1445283 A GB1445283 A GB 1445283A GB 3601374 A GB3601374 A GB 3601374A GB 3601374 A GB3601374 A GB 3601374A GB 1445283 A GB1445283 A GB 1445283A
Authority
GB
United Kingdom
Prior art keywords
formula
compounds
biphenylyl
bromo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3601374A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of GB1445283A publication Critical patent/GB1445283A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • C07F9/5407Acyclic saturated phosphonium compounds

Abstract

1445283 Diphenyl derivatives DR KARL THOMAE GmbH 15 Aug 1974 [16 Aug 1973] 36013/74 Headings C2C and C2P The invention comprises compounds of the general Formula I wherein R 1 represents a chlorine or fluorine atom and B represents a hydroxyl group, an alkoxy or aralkoxy group or an amino group and basic salts of those compounds of Formula I wherein B represents a hydroxyl group. The compounds of Formula I are used as pharmaceuticals. Many methods for the preparation of compounds of Formula I are described. Examples 16(a) and 17(a) describe respectively the preparation of 2 - (2 - fluoro [and 2 - chloro] - 4 - biphenyl) - 1 - ethoxycarbonyl - 1 - propylidene triphenyl - phosphorane by refluxing in absolute ethyl acetate ethoxycarbonyl-methylidene triphenyl phosphorane with bromo - 1- (2 - fluoro - 4 - biphenylyl)ethane and 1 - (2- chloro - 4 - biphenylyl) - 1 - bromo - ethane respectively.
GB3601374A 1973-08-16 1974-08-15 Biphenyl derivatives and pharmaceutical compositions thereof Expired GB1445283A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19732341507 DE2341507A1 (en) 1973-08-16 1973-08-16 NEW BIPHENYL DERIVATIVES AND METHOD OF MANUFACTURING

Publications (1)

Publication Number Publication Date
GB1445283A true GB1445283A (en) 1976-08-11

Family

ID=5889963

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3601374A Expired GB1445283A (en) 1973-08-16 1974-08-15 Biphenyl derivatives and pharmaceutical compositions thereof

Country Status (18)

Country Link
JP (1) JPS5049262A (en)
AT (1) AT331235B (en)
AU (1) AU7243074A (en)
BE (1) BE818952A (en)
DD (1) DD114590A5 (en)
DE (1) DE2341507A1 (en)
DK (1) DK433674A (en)
ES (11) ES446694A1 (en)
FI (1) FI238974A (en)
FR (1) FR2240722B1 (en)
GB (1) GB1445283A (en)
HU (1) HU168875B (en)
IL (1) IL45464A0 (en)
NL (1) NL7410292A (en)
NO (1) NO742802L (en)
RO (1) RO72842A (en)
SE (1) SE7410436L (en)
ZA (1) ZA745257B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885404A (en) * 1985-07-12 1989-12-05 The Upjohn Company Flurbiprofen intermediate
US9206143B2 (en) 2008-03-19 2015-12-08 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
CN1138764C (en) * 1997-04-21 2004-02-18 住友制药株式会社 Isoxazole derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885404A (en) * 1985-07-12 1989-12-05 The Upjohn Company Flurbiprofen intermediate
US9206143B2 (en) 2008-03-19 2015-12-08 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US9212155B2 (en) 2008-03-19 2015-12-15 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders

Also Published As

Publication number Publication date
BE818952A (en) 1975-02-17
ES446693A1 (en) 1977-06-16
ES446701A1 (en) 1977-06-01
ES446695A1 (en) 1977-07-01
FR2240722A1 (en) 1975-03-14
ZA745257B (en) 1976-04-28
DK433674A (en) 1975-04-28
ES446700A1 (en) 1977-06-01
NL7410292A (en) 1975-02-18
ES446694A1 (en) 1977-06-16
RO72842A (en) 1981-11-04
JPS5049262A (en) 1975-05-01
ES446692A1 (en) 1977-06-16
ES446690A1 (en) 1977-07-01
FR2240722B1 (en) 1978-07-28
DE2341507A1 (en) 1975-02-27
ES446699A1 (en) 1977-06-16
SE7410436L (en) 1975-02-17
NO742802L (en) 1975-03-17
AT331235B (en) 1976-08-10
AU7243074A (en) 1976-02-19
FI238974A (en) 1975-02-17
DD114590A5 (en) 1975-08-12
ES446689A1 (en) 1977-06-16
ATA577674A (en) 1975-11-15
ES446691A1 (en) 1977-06-16
ES446698A1 (en) 1977-06-16
HU168875B (en) 1976-07-28
IL45464A0 (en) 1974-11-29

Similar Documents

Publication Publication Date Title
AU645709B2 (en) New 2,4-thiazolidinedione compounds, process for preparing them and pharmaceutical compositions containing them
ATE18765T1 (en) PHARMACEUTICAL COMPOSITIONS.
ES8201168A1 (en) Cephalosporin derivatives, pharmaceutical compositions and process for their preparation.
NO822222L (en) PROCEDURE FOR PREPARING PYRROLIDE INGREDIENTS
ATE14884T1 (en) S-ADENOSINYLMETHIONINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES AS THE ACTIVE SUBSTANCE.
GB1445283A (en) Biphenyl derivatives and pharmaceutical compositions thereof
LV10949A (en) Substituted 4-Phenyl-4-piperidinecarboxamide Compound for Pharmaceutical Formulation
ES2116612T3 (en) NEW BIS-NAFTALIMIDES FOR THE TREATMENT OF CANCER.
DK0490816T3 (en) Fluorine Compounds as Aromatase Inhibitors.
GB1322370A (en) Hydroxycrotonic acid derivatives their preparation and compositions containing them and intermediates for the preparation of the same
ES8402829A1 (en) Thiazoline derivatives, their preparation and use and pharmaceutical preparations containing them.
NL930024I2 (en) Process for the preparation of new phenoxypropylamine derivatives and their salts, as well as pharmaceutical preparations containing these compounds as an active component.
ES8100015A1 (en) 2-(4-Aminopiperidino)-3.4-dihydroquinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use.
DK114186D0 (en) IMIDAZOLYL COMPOUNDS OR PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS
FR2395266A1 (en) -LACTONE MONOMERS AND THEIR POLYMERS, SALTS AND DERIVATIVES, USED IN PARTICULAR AS COLORS, TANNING ADDICTS AND MEDICINAL PRODUCTS
FR2205515B1 (en)
IE40624B1 (en) Phenylpropanolamines
GB1433959A (en) Bis-thioureido benzene derivatives
GB1416281A (en) N-benzene-sulphonyl-erythromycylamine derivatives
ES400624A1 (en) Pharmaceutical compositions
GB1333565A (en) Therapeutic compositions
GB1281201A (en) 2-iminobenzodiazepine derivatives
ES450211A1 (en) Diazaborines and drug compositions
GB1428868A (en) Spa 8- alpha-nicotinolyxyethyl-caffeine derivatives
GB1234967A (en) Alkanolamine derivatives

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee